|
42 Companies |
|
55 Products |
|
55 Products |
|
62 Mechanisms of Action |
|
3 Trials |
|
315 News |
|
| «1234567» |
- erlotinib / Generic mfg.
Trial termination, Surgery: Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin (clinicaltrials.gov) - May 27, 2016
P2, N=10, Terminated, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Lack of primary outcome efficacy.
- || Veregen (sinecatechins) / Sinphar Pharma, Medigene
Trial completion, Trial primary completion date: Topical Green Tea Ointment in Treatment of Superficial Skin Cancer (clinicaltrials.gov) - May 18, 2016
P2/3, N=42, Completed, Sponsor: Maastricht University Medical Center
Completed --> Terminated; Lack of primary outcome efficacy. Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2015
- ||||||| MDX-1379 / BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Combination therapy, Monotherapy, Metastases: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - May 16, 2016
P3, N=1783, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Sep 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Online Tailored Interventions & Relational Agents for Exercise and Sun Protection (clinicaltrials.gov) - May 13, 2016
P=N/A, N=1364, Completed, Sponsor: University of Rhode Island
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> May 2013
- Biomarker, Trial withdrawal, Trial primary completion date, IO biomarker, Metastases: Biomarker Correlates of Hypoxia in Metastatic Melanoma (clinicaltrials.gov) - May 9, 2016
P2, N=0, Withdrawn, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> May 2013 Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Feb 2016
- || STM-434 / Atara
Trial primary completion date, Combination therapy, Metastases: Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (clinicaltrials.gov) - Apr 25, 2016
P1, N=81, Recruiting, Sponsor: Santa Maria Biotherapeutics
Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Feb 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- Young TIL / National Cancer Institute
Enrollment change, Trial termination, Metastases: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 18, 2016
P2, N=18, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> Jul 2017 N=35 --> 18 | Recruiting --> Terminated; Study was closed prematurely due to slow and insufficient accrual.
- Erivedge (vismodegib) / Roche
Trial primary completion date, Surgery: Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Stanford University
N=35 --> 18 | Recruiting --> Terminated; Study was closed prematurely due to slow and insufficient accrual. Trial primary completion date: Nov 2015 --> Nov 2017
- arsenic trioxide / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=5, Completed, Sponsor: Stanford University
Trial primary completion date: Nov 2015 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Nov 2013
- Trial primary completion date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Nov 2013 Trial primary completion date: Dec 2015 --> Dec 2016
- vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2016
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=55, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- Enrollment change, Trial termination: Post-Approval Study of MelaFind (clinicaltrials.gov) - Mar 11, 2016
P=N/A, N=487, Terminated, Sponsor: MELA Sciences, Inc.
Trial primary completion date: Jan 2017 --> Jan 2018 N=720 --> 487 | Recruiting --> Terminated; FDA withdrew requirement to complete study
- Tavo (tavokinogene telsaplasmid) / OncoSec
Trial primary completion date: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=15, Active, not recruiting, Sponsor: OncoSec Medical Incorporated
N=720 --> 487 | Recruiting --> Terminated; FDA withdrew requirement to complete study Trial primary completion date: Sep 2015 --> Jun 2016
- erlotinib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Surgery: Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin (clinicaltrials.gov) - Mar 5, 2016
P2, N=10, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Jun 2016 Active, not recruiting --> Completed | N=40 --> 10 | Trial primary completion date: Mar 2017 --> Mar 2016
- Enrollment closed, Enrollment change, Metastases: Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 29, 2016
P2, N=6, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=40 --> 10 | Trial primary completion date: Mar 2017 --> Mar 2016 Recruiting --> Active, not recruiting | N=35 --> 6
- |||| Promune (agatolimod) / Pfizer
Trial completion: CPG 7909 Injection in Melanoma (clinicaltrials.gov) - Feb 27, 2016
P2, N=184, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=35 --> 6 Recruiting --> Completed
- Trial completion, IO biomarker: OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=98, Completed, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Completed Terminated --> Completed
- ||| PSMA-targeted docetaxel (BIND-014) / Pfizer
Trial completion, Enrollment change, Metastases: A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Feb 9, 2016
P1, N=58, Completed, Sponsor: BIND Therapeutics
Terminated --> Completed Active, not recruiting --> Completed | N=30 --> 58
- |||| veliparib (ABT-888) / AbbVie
Trial completion, Combination therapy, Metastases: A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma (clinicaltrials.gov) - Feb 9, 2016
P2, N=346, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed | N=30 --> 58 Active, not recruiting --> Completed
- carboplatin / Generic mfg.
Trial primary completion date: Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck (clinicaltrials.gov) - Jan 26, 2016
P3, N=321, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2016
- Trial primary completion date: New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=277, Recruiting, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Trial primary completion date: An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=100, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- itraconazole / Generic mfg.
Biomarker, Enrollment closed, Trial primary completion date: Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas (clinicaltrials.gov) - Jan 16, 2016
P2, N=15, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Dec 2015 --> Jun 2016 Suspended --> Active, not recruiting | Trial primary completion date: Jul 2012 --> Dec 2016
- Young TIL / National Cancer Institute
Trial primary completion date, Metastases: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 31, 2015
P2, N=35, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting | Trial primary completion date: Jul 2012 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Enrollment open: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome (clinicaltrials.gov) - Dec 21, 2015
P2, N=3, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- Trial primary completion date: Sunbit UV Measuring Device to Track Sun Behavior (clinicaltrials.gov) - Dec 11, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Zurich
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Aug 2017
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, Metastases: A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma (clinicaltrials.gov) - Nov 17, 2015
P2, N=346, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Aug 2015 --> Aug 2017 Trial primary completion date: Aug 2015 --> Dec 2015
- Biomarker, Enrollment change, IO biomarker, Metastases: Biomarker Correlates of Hypoxia in Metastatic Melanoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=6, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Aug 2015 --> Dec 2015 N=36 --> 6
- Trial completion: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin (clinicaltrials.gov) - Sep 21, 2015
P2, N=18, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 6 Active, not recruiting --> Completed
- erlotinib / Generic mfg.
Trial primary completion date, Surgery: Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin (clinicaltrials.gov) - Sep 9, 2015
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Mar 2017
- Trial completion, Enrollment change: A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=1234, Completed, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Completed | N=1600 --> 1234
- sirolimus / Generic mfg.
Enrollment change, Trial termination: PROSKIN: Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol (clinicaltrials.gov) - Sep 3, 2015
P4, N=44, Terminated, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=1600 --> 1234 N=280 --> 44 | Active, not recruiting --> Terminated; Insufficient patient recruitment
- Enrollment change: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Aug 26, 2015
P=N/A, N=180, Terminated, Sponsor: Case Comprehensive Cancer Center
N=280 --> 44 | Active, not recruiting --> Terminated; Insufficient patient recruitment N=150 --> 180
- Trial initiation date, Trial primary completion date: Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome (clinicaltrials.gov) - Aug 21, 2015
P2, N=3, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
N=150 --> 180 Initiation date: May 2015 --> Oct 2015 | Trial primary completion date: Dec 2015 --> Dec 2016
- Samcyprone (diphenylcyclopropenone) / Phio Pharma
Enrollment closed, IO biomarker, Immunomodulating: Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) - Aug 14, 2015
P1, N=13, Active, not recruiting, Sponsor: Rockefeller University
Initiation date: May 2015 --> Oct 2015 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- | temozolomide / Generic mfg., decitabine / Generic mfg.
Trial completion, Metastases: Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma (clinicaltrials.gov) - Aug 14, 2015
P1/2, N=39, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || epacadostat (INCB024360) / Incyte
Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=136, Active, not recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Feb 2016
- Trial primary completion date, Biopsy: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1, N=100, Active, not recruiting, Sponsor: University of Utah
Trial primary completion date: Oct 2014 --> Feb 2016 Trial primary completion date: Jul 2015 --> Jul 2016
- Clinical data, Enrollment change, Trial termination, Trial primary completion date: SK01: Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=11, Terminated, Sponsor: University of Florida
Trial primary completion date: Jul 2015 --> Jul 2016 N=174 --> 11 | Recruiting --> Terminated | Trial primary completion date: Oct 2056 --> Jul 2015; Slow enrollment, feasibility issues
- Tavo (tavokinogene telsaplasmid) / OncoSec
Trial primary completion date: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=15, Active, not recruiting, Sponsor: OncoSec Medical Incorporated
N=174 --> 11 | Recruiting --> Terminated | Trial primary completion date: Oct 2056 --> Jul 2015; Slow enrollment, feasibility issues Trial primary completion date: Jun 2015 --> Sep 2015
- carboplatin / Generic mfg., temozolomide / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Trial termination, Metastases: Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma (clinicaltrials.gov) - Jun 20, 2015
P2, N=20, Terminated, Sponsor: New Mexico Cancer Care Alliance
Trial primary completion date: Jun 2015 --> Sep 2015 N=50 --> 20 | Active, not recruiting --> Terminated; Low accrual; target accrual not met
- dasatinib / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 18, 2015
P2, N=7, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 20 | Active, not recruiting --> Terminated; Low accrual; target accrual not met Terminated --> Completed | Trial primary completion date: Feb 2011 --> Apr 2012
- Trial primary completion date, Metastases: Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=35, Recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed | Trial primary completion date: Feb 2011 --> Apr 2012 Trial primary completion date: Jun 2016 --> Dec 2017
- cisplatin / Generic mfg., vinblastine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma (clinicaltrials.gov) - May 7, 2015
P2, N=7, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2016 --> Dec 2017 Active, not recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Apr 2013 --> Oct 2013
- Trial completion: Pilot Investigation of Behavioral Alternatives to Indoor Tanning (clinicaltrials.gov) - May 6, 2015
P=N/A, N=74, Completed, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Apr 2013 --> Oct 2013 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer (clinicaltrials.gov) - May 6, 2015
P=N/A, N=29, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Suspended --> Completed | N=110 --> 29 | Trial primary completion date: Jun 2015 --> Feb 2013
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging (clinicaltrials.gov) - May 4, 2015
P2, N=5, Completed, Sponsor: Navidea Biopharmaceuticals
Suspended --> Completed | N=110 --> 29 | Trial primary completion date: Jun 2015 --> Feb 2013 Recruiting --> Completed | N=12 --> 5 | Trial primary completion date: Dec 2015 --> Mar 2015
- | Trial completion: Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=12 --> 5 | Trial primary completion date: Dec 2015 --> Mar 2015 Recruiting --> Completed
- Trial primary completion date: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Trial primary completion date: Nov 2014 --> Dec 2015